What If You're Asked to Promote Off-Label Drug Use?

Imagine your manager hands you next quarter's sales targets. The numbers only work if doctors prescribe your company's drug for a condition the FDA never approved it to treat. What do you do?

The first thing to know is that doctors may legally prescribe approved drugs for unapproved uses, but manufacturers face strict limits on promoting those uses. If you're asked to cross that line, you can decline, write down what happened, raise it through internal compliance channels, and consider reporting it to the government if the conduct continues. Some off-label promotion leads to false claims to Medicare and Medicaid, which is why these decisions can carry real legal weight.

The issue most often touches pharmaceutical sales representatives, medical science liaisons, and marketing staff. They may face targets that reward off-label prescriptions without clear guidance on where the line sits. Some of the largest False Claims Act settlements in the pharmaceutical industry have involved off-label marketing, so the stakes are high for patients, careers, and companies alike.

What Off-Label Promotion Means for Pharma Employees

Off-label use means prescribing a drug for a condition, dose, age group, or method the U.S. Food and Drug Administration has not approved. A physician can make that choice based on medical judgment, and the practice is both legal and common. The restrictions fall mainly on how manufacturers market their products.

Under federal law, drug companies generally may promote a drug only for its approved uses. Marketing it for unapproved uses can cause it to be considered misbranded under the Federal Food, Drug, and Cosmetic Act. The rules on sharing scientific information about unapproved uses are detailed and have shifted over time, so individual situations can get complicated.

For employees, the practical question is what they are actually being asked to say or do. Answering a doctor's unsolicited question through approved medical channels is treated differently from pitching an unapproved use on a sales call. Company policies usually explain how to handle such questions. If you're unsure, asking the compliance department for written guidance can clear things up.

When Off-Label Promotion Becomes a Fraud Concern

Off-label promotion turns into a fraud problem when it leads to false claims for government payment. Medicare Part D and Medicaid generally cover drugs only for medically accepted indications. If a company promotes uses that fall outside those coverage rules, the resulting prescriptions may be billed to government programs improperly.

These cases are often brought under the False Claims Act, which applies to anyone who knowingly causes false claims to be submitted. A manufacturer doesn't have to submit the claim itself. Causing pharmacies or providers to do so can be enough. Many states also have their own false claims laws covering Medicaid spending.

Off-label promotion also tends to show up alongside other misconduct, such as paying doctors to prescribe, disguising payments as consulting fees, or making false statements about a drug's safety. Learning how pharma fraud is commonly structured can help employees recognize when a sales strategy crosses legal lines.

Warning Signs of Improper Off-Label Sales Practices

Certain patterns suggest a company may be encouraging off-label promotion:

• Managers set targets that can only be met through prescriptions for unapproved uses.

• Representatives are told to call on specialists who rarely treat the drug's approved condition.

• Training or sales materials include unofficial slide decks, talking points describing unapproved benefits, or instructions to share studies outside approved channels.

• Employees are asked to keep certain topics out of writing.

Financial arrangements can raise flags too. Speaker programs that pay high-prescribing doctors, meals with little educational content, and grants tied to prescribing may all raise kickback concerns. The federal Anti-Kickback Statute generally prohibits offering anything of value to induce prescriptions or referrals paid for by federal health programs.

Records to Keep When Asked to Promote Off-Label Use

Clear records show what you were asked to do and when. Note the date, who made the request, what was said, and who else was present. Notes written soon after a conversation tend to be more reliable than memories reconstructed later.

Relevant documents might include emails, sales targets, call plans, training materials, and compensation plans. Be careful, though, about how you collect and store company documents. Taking confidential files or patient information can create legal problems of its own, so it's wise to get legal guidance before copying anything.

Record your own responses as well. A note showing that you declined a request or raised a concern internally can matter later, and it can help if you face retaliation for speaking up.

Reporting Options for Suspected Pharmaceutical Fraud

Many employees begin by raising concerns with a supervisor, the compliance department, or a company ethics hotline. Internal reporting may resolve the issue and creates a record that you spoke up. It isn't always required before contacting government authorities, however.

Outside the company, you can contact the HHS Office of Inspector General or the FDA's Bad Ad Program, which reviews concerns about misleading drug promotion. Employees with detailed knowledge of fraud against federal programs may also be able to file a qui tam lawsuit under the False Claims Act, which is filed under seal. Resources that explain how to report pharma fraud can help you compare these options.

Federal law also protects against retaliation. The False Claims Act covers employees who are fired, demoted, or harassed for lawful efforts to stop violations. Whether protection applies depends on the facts, so it's worth understanding the rules before you act.

How Foreign Bribery Risks Arise in Pharmaceutical Sales

Companies that sell overseas may also face risk under the Foreign Corrupt Practices Act (FCPA). It generally prohibits covered companies and individuals from offering anything of value to foreign officials to obtain or keep business. In many countries, doctors at state-run hospitals may count as foreign officials.

The warning signs resemble domestic kickback schemes: payments routed through distributors, travel or gifts for doctors at government hospitals, and consulting fees with no clear purpose. Inaccurate records used to hide such payments may also violate the FCPA's accounting provisions, which apply to publicly traded companies.

Employees who learn of possible foreign bribery have several reporting paths. The SEC's whistleblower program accepts tips about FCPA violations involving publicly traded companies. Because eligibility rules and enforcement priorities can change, check the SEC's current guidance to see which program fits your situation.

Documenting Off-Label Requests Helps Protect You

If you're asked to promote off-label drug use, you can decline, document the request, and raise your concerns through compliance channels. Doctors may prescribe off-label, but manufacturers face strict limits on promotion, and knowing the difference helps you make informed choices.

When off-label promotion is tied to false claims, kickbacks, or foreign bribery, government reporting options and whistleblower protections may apply. Those protections depend on the facts and the law involved. Careful records and a clear understanding of the rules help you respond responsibly.